| Literature DB >> 33458693 |
Kerstin B Kaufmann1, Weijia Wang2, Michelle Chan-Seng-Yue1,3, Stephanie Z Xie4, Olga I Gan1, Elisa Laurenti1,5, Laura Garcia-Prat1, Shin-Ichiro Takayanagi1,6, Stanley W K Ng7, ChangJiang Xu8,9, Andy G X Zeng1,9, Liqing Jin1, Jessica McLeod1, Elvin Wagenblast1, Amanda Mitchell1, James A Kennedy1,10,11, Qiang Liu1, Héléna Boutzen1, Melissa Kleinau1, Joseph Jargstorf1, Gareth Holmes1, Yang Zhang2, Veronique Voisin8,9, Gary D Bader8,9, Jean C Y Wang1,10,11, Yusuf A Hannun12, Chiara Luberto13, Timm Schroeder2, Mark D Minden1,10,11,14, John E Dick4,9.
Abstract
Acute myeloid leukemia (AML) is a caricature of normal hematopoiesis, driven from leukemia stem cells (LSC) that share some hematopoietic stem cell (HSC) programs including responsiveness to inflammatory signaling. Although inflammation dysregulates mature myeloid cells and influences stemness programs and lineage determination in HSC by activating stress myelopoiesis, such roles in LSC are poorly understood. Here, we show that S1PR3, a receptor for the bioactive lipid sphingosine-1-phosphate, is a central regulator which drives myeloid differentiation and activates inflammatory programs in both HSC and LSC. S1PR3-mediated inflammatory signatures varied in a continuum from primitive to mature myeloid states across AML patient cohorts, each with distinct phenotypic and clinical properties. S1PR3 was high in LSC and blasts of mature myeloid samples with linkages to chemosensitivity, while S1PR3 activation in primitive samples promoted LSC differentiation leading to eradication. Our studies open new avenues for therapeutic target identification specific for each AML subset.Entities:
Keywords: Acute myeloid leukemia; S1PR3; TNFα via NF-κB; hematopoietic stem cells; myeloid differentiation
Mesh：
Substances：
Year: 2020 PMID： 33458693 PMCID： PMC7116590 DOI： 10.1158/2643-3230.BCD-20-0155
Source DB: PubMed Journal: Blood Cancer Discov ISSN： 2643-3230